Citation Impact
Citing Papers
A "Silent" Polymorphism in the MDR 1 Gene Changes Substrate Specificity
2006 StandoutScience
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 StandoutScience
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Multidrug resistance in cancer: role of ATP–dependent transporters
2002 Standout
Sensitivity of Non-Small-Cell Lung Cancer Cell Lines Established from Patients Treated with Prolonged Infusions of Paclitaxel
2003
Catalytic Asymmetric Three‐Component Synthesis of Homoallylic Amines
2013 StandoutNobel
Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis
1996 Standout
Targeting by affinity–matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform
1997 StandoutNobel
Retargeting serum immunoglobulin with bispecific diabodies
1997 StandoutNobel
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
1996 Standout
Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumour antibody
1995
Principles of nanoparticle design for overcoming biological barriers to drug delivery
2015 Standout
Interactions between cancer cells and the microvasculature: a rate-regulator for metastasis
1989
Paclitaxel (Taxol)
1995 Standout
Vascular targeting—a new approach to the therapy of solid tumors
1994
Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine*
1997 Standout
Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning
1996 Standout
Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma
1995 Standout
Nanocarriers as an emerging platform for cancer therapy
2007 Standout
Treatment of Anaplastic Thyroid Carcinoma with Paclitaxel: Phase 2 Trial Using Ninety-Six-hour Infusion
2000
Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth
1997 Standout
Glycans in cancer and inflammation — potential for therapeutics and diagnostics
2005 StandoutNobel
PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
1998 Standout
Chemical remodelling of cell surfaces in living animals
2004 StandoutNatureNobel
INTERFERON-?? TREATMENT OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER IN RECIPIENTS OF SOLID ORGAN TRANSPLANTS1
1998
Cancer-associated carbohydrates identified by monoclonal antibodies
1990
Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma.
1998
ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.
1994
Metabolic Labeling of Sialic Acids in Living Animals with Alkynyl Sugars
2009 StandoutNobel
Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery
2012 Standout
Clinical trials of p-glycoprotein reversal in solid tumours
1996
Calmodulin as a Versatile Tag for Antibody Fragments
1995 StandoutNobel
Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.
1995
Hematopoietic Stem-Cell Transplantation
2006 Standout
Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer.
1990
Laminin and Other Basement Membrane Components
1987
Phase I Study of Intravenous PSC‐833 and Doxorubicin: Reversal of Multidrug Resistance
2001
P-glycoprotein Expression: Critical Determinant in the Response to Osteosarcoma Chemotherapy
1997
Evidence for a precursor of the high-affinity metastasis-associated murine laminin receptor
1989
Pharmacological considerations in the modulation of multidrug resistance
1996
Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
1991 Standout
Primary brain tumours in adults
2012 Standout
Primary central nervous system lymphoma
1988
Mechanisms of Bone Metastasis
2004 Standout
Nanoparticles, Proteins, and Nucleic Acids: Biotechnology Meets Materials Science
2001 Standout
Metabolic selection of glycosylation defects in human cells
2001 StandoutNobel
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
2002 Standout
Kaposi's Sarcoma
2000 Standout
Inferences, questions and possibilities in Toll-like receptor signalling
2004 StandoutNatureNobel
Epstein–Barr Virus Infection
2000 Standout
Cancer of the Ovary
2004 Standout
Phase I Study of Infusional Paclitaxel in Combination With the P-Glycoprotein Antagonist PSC 833
2001
Integrins: A family of cell surface receptors
1987 Standout
Cancer Markers of the 1990s: Comparison of the New Generation of Markers Defined by Monoclonal Antibodies and Oncogene Probes to Prototypic Markers
1990
Exploiting Differences in Sialoside Expression for Selective Targeting of MRI Contrast Reagents
1999 StandoutNobel
Integrins: Versatility, modulation, and signaling in cell adhesion
1992 Standout
Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
2000 Standout
Cytokine-induced respiratory burst of human neutrophils: dependence on extracellular matrix proteins and CD11/CD18 integrins.
1989
Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.
1992
Clinical Studies with Modulators of Multidrug Resistance
1995
Genetic Polymorphism in MDR-1: A Tool for Examining Allelic Expression in Normal Cells, Unselected and Drug-Selected Cell Lines, and Human Tumors
1998
Functional mapping of disease susceptibility loci using cell biology
2006 StandoutNobel
Uranium-loaded apoferritin with antibodies attached: molecular design for uranium neutron-capture therapy.
1992
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Altered levels of laminin receptor mRNA in various human carcinoma cells that have different abilities to bind laminin.
1986
Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model
1998 StandoutScience
Signal transduction for chemotaxis and haptotaxis by matrix molecules in tumor cells.
1990
The cell substrate attachment (CSAT) antigen has properties of a receptor for laminin and fibronectin.
1985
Murine epidermal growth factor (EGF) fragment (33-42) inhibits both EGF- and laminin-dependent endothelial cell motility and angiogenesis.
1995
Growth Factors and Cancer
1991 StandoutScience
Risk-assessment in diffuse large cell lymphoma at first relapse. A study by the Italian Intergroup for Lymphomas.
2001
Structural Investigations into the Stereochemistry and Activity of a Phenylalanine-2,3-aminomutase from Taxus chinensis
2014 StandoutNobel
THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS
1997
Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo.
1997
Distribution of a putative cell surface receptor for fibronectin and laminin in the avian embryo.
1986
GENETIC ANALYSIS OF HOST RESISTANCE: Toll-Like Receptor Signaling and Immunity at Large
2006 StandoutNobel
Isolation of the thrombospondin membrane receptor.
1987
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
1999 StandoutScience
Neurexins: Synaptic Cell Surface Proteins Related to the α-Latrotoxin Receptor and Laminin
1992 StandoutScienceNobel
Endocytosis and recycling of the fibronectin receptor in CHO cells.
1989
Thrombospondin stimulates motility of human neutrophils.
1990 StandoutNobel
New Perspectives in Cell Adhesion: RGD and Integrins
1987 StandoutScience
Thyroid carcinoma
2003 Standout
Engineering Chemical Reactivity on Cell Surfaces Through Oligosaccharide Biosynthesis
1997 StandoutScienceNobel
Works of G Bryant being referenced
EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.
1993
Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas.
1995
Radiolabeled monoclonal antibody B72.3 localization in metastatic lesions of colorectal cancer patients
1987
Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.
1994
Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy.
1995
Monoclonal antibodies to the human laminin receptor recognize structurally distinct sites
1985
Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy.
1995
A Role for the Laminin Receptor in Leukocyte Chemotaxis
1987
The Laminin Receptor and Basement Membrane Dissolution: Role in Tumour Metastasis
1984
Local distribution and concentration of intravenously injected 131I-9.2.27 monoclonal antibody in human malignant melanoma.
1989
Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma.
1987
Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3
1987